Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

2775 - Indicators of non-participation in cervical cancer screening: Results from the EDIFICE 6 survey

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Presenters

Thibault de La Motte Rouge

Authors

T. de La Motte Rouge1, S. Couraud2, F. Eisinger3, M. Roupret4, L. Brignoli-Guibaudet5, C. Lhomel6, L. Greillier7, J. Viguier8, J.F. Morère9

Author affiliations

  • 1 Medical Oncology, Centre Eugene - Marquis, 35042 - Rennes/FR
  • 2 Department Of Respiratory Diseases And Thoracic Oncology, Centre Hospitalier Lyon Sud, 69495 - Pierre Bénite/FR
  • 3 Département D'anticipation Et De Suivi Du Cancer Dasc, Institute Paoli Calmettes, 13274 - Marseille/FR
  • 4 Medical Oncology, Hôpital Universitaire Pitié-Salpêtrière, 75013 - Paris/FR
  • 5 Statistics, Kantar Health, 75014 - Paris/FR
  • 6 Medical, Roche, 9265000 - Boulogne-Billancourt/FR
  • 7 Department Of Multidisciplinary Oncology And Therapeutic Innovations, Hopital St. Marguerite Assistance Publique Hopitaux de Marseille, 13009 - Marseille/FR
  • 8 Ccdc 37, Hôpital Bretonneau, 37044 - Tours/FR
  • 9 Medical Oncology Department, AP-HP, Hôpital Paul Brousse, 94800 - Villejuif/FR
More

Resources

Abstract 2775

Background

Cervical cancer (CC) screening is a long-standing practice in France. Since the 1980s, individual screening has led to a substantial reduction in the frequency of these tumors and the associated mortality. However the process is not optimal and an organized program is about to be implemented at a national level in France. In this context, it is important to have a clear insight into the characteristics of women who are resistant to CC screening.

Methods

The French nationwide observational survey, EDIFICE 6, was conducted online from 26 June-28 to July 2017 on a core sample of 12 046 individuals (age, 18-69 years). Representativeness was ensured by quota sampling on age, gender, profession, and stratification by geographical area and type of urban district. Multivariate stepwise logistic regression analysis was conducted to identify factors likely to explain non-uptake of CC screening. The present analysis included 4499 women (age, 25-65 years) with no history of cancer.

Results

Of those who had never taken part in a screening program, 12% (N = 539) were in the target population for CC screening. Compared to women who had at least one screening test in their life time, the population of never-screened women was characterized by a lower mean age (38±11 yrs vs 44±12 yrs, P<0.05) and higher proportions of single women (48% vs 20%, P<0.05), socially vulnerable individuals (59% vs 38%, P<0.05), and never-smokers (69% vs 49%, P<0.05). In multivariate analysis, items significantly (P<0.05) associated with not undergoing CC screening included living alone (OR=2.26, 95% CI [1.85-2.75]), social vulnerability (OR=1.95 [1.59-2.40]), belonging to the socio-professional categories of unskilled workers (OR=1.89 [1.17-2.94]), skilled manual workers and supervisory or clerical workers (OR=1.80 [1.02-3.05]), and higher managerial and professional occupations (OR=1.74 [1.32-2.28]). The most frequently cited reasons for not undergoing screening were "I don't feel concerned" (40%) and “individual negligence/not a priority” (31%).

Conclusions

Economically active women but also socially vulnerable women, particularly those who are younger, are reluctant to undergo CC screening. These findings are important, notably for vulnerable women who are more at risk of CC.

Clinical trial identification

Editorial Acknowledgement

Medical writing assistance was provided by Potentiel d’Action (France)

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings